6 research outputs found

    Hitting cancer's sweet spot

    No full text

    Redox-mediated suberoylanilide hydroxamic acid sensitivity in breast cancer

    No full text
    Vorinostat (suberoylanilide hydroxamic acid; SAHA) is a histone deacetylase inhibitor (HDACi) approved in the clinics for the treatment of T-cell lymphoma and with the potential to be effective also in breast cancer. We investigated the responsiveness to SAHA in human breast primary tumors and cancer cell lines

    Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?

    No full text
    corecore